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Background: Lipegfilgrastim (Lonquex®) has demonstrated to be non-inferior to
pegfilgrastim (Neulasta®) in reducing the duration of severe neutropenia (SN) in
patients with stage II−IV breast cancer. Compared to pegfilgrastim, lipegfilgrastim also
demonstrated statistically significant lower time to ANC recovery in cycles 1–3, lower
incidence of SN in cycle 2 and lower depth of absolute neutrophil count (ANC) nadir in
cycles 2 and 3. The aim of this study was to quantify the cost utility of lipegfilgrastim
compared to pegfilgrastim in stage II−IV breast cancer patients, taking the perspective
of the Belgian payer over a lifetime horizon.
Methods: Two Markov models were developed to track on- and post-chemotherapy
related complications, including SN, febrile neutropenia (FN), chemotherapy dose delay,
chemotherapy relative dose intensity of less than 85%, infection, death rates, and quality-
adjusted life years (QALYs). Data on costs (2015 value) and effects were obtained from
literature, national references, and complemented by a survey of clinical experts using
a modified Delphi method. Both deterministic and probabilistic sensitivity analyses were
carried out. Outcomes measures included costs, QALYs and life-years (LY).
Results: At current equivalent price of e1,169, treatment with lipegfilgrastim was
associated with overall costs of e9,845 vs. e10,208 for pegfilgrastim and overall
QALYs of 13.977 vs. 13.925 for pegfilgrastim. Life expectancy was increased by 21
days (or 0.058 LY gained). The difference in costs stem from avoided infection, SN
and FN cases in the lipegfilgrastim compared to the pegfilgrastim group. Similarly,
the difference in QALYs was explained by the difference in the number of patients
in the chemotherapy/G-CSF Markov state followed by infection and FN between
lipegfilgrastim and pegfilgrastim. The probability of lipegfilgrastim to be cost-effective
compared to pegfilgrastim was 68, 79, and 83% at the willingness-to-pay thresholds
(WTP) of e10,000, e30,000 and e50,000 per QALY gained, respectively. At a
WTP threshold of e30,000 per QALY gained, lipegfilgrastim was cost-effective up
to e1,500 across all age bands and cancer stages, compared to the current price.
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Conclusions: Lipegfilgrastim is a cost-effective use of health care resources in patients
with stage II-IV breast cancer.
Keywords: lipegfilgrastim, pegfilgrastim, breast cancer, cost-utility, febrile neutropenia, severe neutropenia
INTRODUCTION
Chemotherapy-induced neutropenia (CIN), a common side
effect of cancer chemotherapy, is a major risk factor for
infection-related morbidity and mortality and a significant dose-
limiting toxicity (Aapro et al., 2011). The duration and severity
of CIN depend on various factors including type of cancer,
patient-specific risk factors, individual disease characteristics,
and chemotherapy regimen (Crawford et al., 2004). Prolonged
and severe CIN may lead to serious complications in the short-
term due to the increased risk of febrile neutropenia (FN) and
infections. As a result of CIN, the subsequent chemotherapy
cycles may be delayed to allow for neutrophil recovery; or the
chemotherapy doses may be reduced in an effort to minimize
the incidence of CIN in later cycles (Mucenski and Shogan,
2003). Consequently, when CIN occurs, patient’s quality of
life is impaired and the long-term clinical efficacy and cost-
effectiveness of chemotherapy may be compromised (Trillet-
Lenoir et al., 1993; Crawford et al., 2004; Lyman, 2009).
To counteract the negative impact of CIN, short and long-
acting recombinant granulocyte colony-stimulating factors (G-
CSFs) are used to promote the proliferation, differentiation,
and maturation of neutrophils, thereby reducing the duration
and severity of CIN as well as the incidence of severe
neutropenia (SN), FN and infection-related mortality (Crawford
et al., 1991; Trillet-Lenoir et al., 1993; Kuderer et al., 2007;
Wang et al., 2015). The data suggest that long-acting G-
CSFs are more effective compared to short-acting G-CSFs
in terms of incidence of FN (Mitchell et al., 2016). They
are also less burdensome to administer (once per cycle with
long-acting vs. up to 11 injections with short-acting G-CSFs).
Therefore, in Belgium, long-acting -G-CSFs are more often
used than short-acting G-CSFs. Current market approved long-
acting compounds include pegfilgrastim (Neulasta R© ; Amgen
Inc.) and lipegfilgrastim (Lonquex R© ; Teva Pharmaceuticals
Europe B.V.); with the glycopegylated G-CSF lipegfilgrastim
presenting distinct pharmacokinetic and pharmacodynamics
properties compared to pegfilgrastim (Hoggatt et al., 2015;
Guariglia et al., 2016). Lipegfilgrastim has a slower clearance
than pegfilgrastim, with a terminal half-life of lipegfilgrastim
shown to be 7−10 h longer than that of pegfilgrastim in
healthy volunteers (Buchner et al., 2014; Guariglia et al.,
2016).
In a randomized, multicenter, active-control phase III trial,
Bondarenko et al. demonstrated that lipegfilgrastim was as
effective as pegfilgrastim in reducing the duration of SN
in patients with breast cancer receiving myelosuppressive
chemotherapy in primary prophylaxis (Bondarenko et al., 2013).
Wang et al. and Bond et al. further confirmed in meta-analyses
that the risk of FN was not significantly different between
lipegfilgrastim and pegfilgrastim with an odds ratio (OR) of 0.98
(95%CI: 0.21–4.53) and a relative risk (RR) of 0.34 (95%CI: 0.05–
2.14), respectively (Bond et al., 2015; Wang et al., 2015). There
were further no differences in hospitalization and antibiotic usage
between the two G-CSFs (Gladkov et al., 2016).
However, Bondarenko et al. reported significant lower
incidence of SN in cycle 2 of chemotherapy in the lipegfilgrastim
group compared to the pegfilgrastim group (8.5% vs. 21.5%; P
= 0.013). The absolute neutrophil count (ANC) nadir (109/L)
after cycles 2-3 was higher in the lipegfilgrastim group compared
to pegfilgrastim group (2.6 vs. 2.0 and 2.5 vs. 2.0; P = 0.019
and P = 0.035, respectively). Similarly, the time to ANC
recovery (days) was −1.59 days shorter for the lipegfilgrastim
group compared to the pegfilgrastim one (−1.59, −1.66, and
−1.34; P = 0.003, P = 0.008, and P = 0.033 for cycles 1, 2,
and 3, respectively). In the lipegfilgrastim group, one patient
experienced FN compared to three patients in the pegfilgrastim
group. Additionally, 31 patients in the lipegfilgrastim group
had their chemotherapy delayed in subsequent cycles with no
dose omissions or reductions in cycles 2−4. In the pegfilgrastim
group, 36 patients received delayed chemotherapy treatment, and
eight patients had dose omissions or reductions in cycles 2−4
(Bondarenko et al., 2013).
Cost-effectiveness analysis is increasingly being used to
guide resource allocation and maximize health benefits as a
result of increasing health expenditures and resulting budgetary
constraints. There are very few studies assessing the cost-
effectiveness of lipegfilgrastim compared to pegfilgrastim. Taking
the Belgian payer perspective, Fust et al. concluded that
pegfilgrastim was cost-effective vs. lipegfilgrastim in patients
with stage II breast cancer using Wang et al.’s risk estimate
for FN of 1.39 (0.54–3.50) for lipegfilgrastim compared to
pegfilgrastim (Fust et al., 2015, 2016; Wang et al., 2015). Wang
et al.’s risk estimate for FN was derived from a mixed treatment
comparison (MTC) using a heterogeneous (i.e., non-breast
cancer specific) cancer population and considering different
studies designs. Kulikov et al., on the other hand, conducted
a comparative pharmacoeconomic analysis of prophylactic use
of lipegfilgrastim, pegfilgrastim, filgrastim, and lenograstim in
the prevention of FN in Russia’s health care setting (Kulikov
et al., 2016). Kulikov et al. concluded that lipegfilgrastim was
the dominant therapy as it allows to increase the number of
patients who responded to prophylaxis of FN while reducing
costs as compared to other G-CSFs. Budget impact analysis,
considering the costs for G-CSF drugs, costs for the treatment
of incurring cases of FN and costs for the management of
adverse events showed that the use of lipegfilgrastim for the
prevention of FN saves budget costs when compared to all
other G-CSF drugs over a 1 year time horizon. The data
on drugs efficacy (measured as the proportion of responders
to prophylaxis of FN by the end of the first year) was
obtained from Bond et al.’s meta-analysis (Bond et al., 2015).
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It should be noted that Bond et al.’s risk estimate for FN
was based on a direct comparison between lipegfilgrastim
and pegfilgrastim in breast cancer patients and in accordance
with the Cochrane Collaboration guidelines (The Cochrane
Collaboration, 2011).
The aim of this study was to calculate the cost-utility
of lipegfilgrastim as compared to pegfilgrastim in reducing
the incidence of CIN and related complications in patients
with breast cancer who received a four-cycle chemotherapy
regimen of 21 days each. The perspective taken was that of
the Belgian third-party payer (the National Institute for Health
andDisability Insurance–INAMI/RIZIV) over a lifetime horizon.
In contrast to current economic evaluations comparing G-
CSF vs. non-G-CSFs or long-acting G-CSF (e.g., pegfilgrastim)
vs. short-acting G-CSF (e.g., filgrastim) that solely track FN
events during chemotherapy cycles (Lyman et al., 2009; Whyte
et al., 2011; Fust et al., 2014, 2015; Kulikov et al., 2016), the
approach taken in this study broadens the scope to additional
CIN complications including incidence of SN, infection and
chemotherapy dose delay. These are clinically meaningful
outcomes considered in clinical guidelines, health technology
appraisals and pharmacoeconomic studies (Aapro et al., 2006;
Rutkowski et al., 2010; SMC. Scottish Medicines Consortium,
2011; Therapeutic Goods Administration, 2011; Johnson et al.,
2014; Massoudi et al., 2017). In particular, SN has been
shown to be significantly associated with both dose delay and
relative dose intensity (RDI) less than 85% (Pettengell et al.,
2008).
MATERIAL AND METHODS
Study Approach
A mathematical model was developed in Excel (Microsoft Corp.,
Redmond, WA) to estimate the lifetime costs and quality-
adjusted life years (QALYs) for lipegfilgrastim and pegfilgrastim.
Two Markov models, one tracking on-chemotherapy cycles and
CIN-related complications (model 1) and one capturing the
impact of RDI on long-term survival (model 2), compared
cumulative costs and outcomes of lipegfilgrastim vs. pegfilgrastim
based on two hypothetical cohorts of 1,000 women, aged 59
years old, 38.6, 47.5. and 13.9% having stage II, III, and IV
breast cancer, respectively (proportions based on the relative
distribution of patients with high risk stage II, stage III, and IV
breast cancer as per the intent-to-treat population in Bondarenko
et al., 2013). The models incorporated three sets of data. Clinical
data, such as health state transition probabilities, were obtained
from Bondarenko et al. and other published studies (Bodey et al.,
1966; Leonard et al., 2003; Kuderer et al., 2006; Chirivella et al.,
2009; Freifeld et al., 2011; Whyte et al., 2011; Fust et al., 2014;
Wang et al., 2015). Transition probabilities and resource use
data pertaining to treatment guidelines and clinical practice in a
Belgian health care setting were validated or adjusted by Belgian
clinicians in a modified Delphi survey. Unit cost data were
derived from publicly accessible governmental databases (CBIP-
BCFI BCfPI, 2015; National Institute for Health and Disability
Insurance (RIZIV-INAMI), 2015b).
Model Structure
The model structure is presented in Figure 1. All patients
enter the model in the state labeled “chemotherapy” upon
administration of chemotherapy agents, such as docetaxel and
anthracycline, and G-CSFs, pegfilgrastim or lipegfilgrastim on
day 2 of each chemotherapy cycle. Dependent on risk factors,
patients either move to chemotherapy-related complication
health states, based on transition probabilities, or remain in
their current health state. Patients with SN or infection were
considered at risk for chemotherapy delay (Pettengell et al.,
2012). Deaths associated with SN, FN and infection were
considered in model 1. Post-chemotherapy deaths from breast
cancer and other causes were considered in model 2, taking into
consideration the impact of RDI (as a result of SN and FN events)
on survival. Table 1 summarizes the model parameters.
Clinical Data and Utilities
On-Chemotherapy Model (Model 1)
The model incorporates the incidence of SN in patients receiving
lipegfilgrastm as compared to pegfilgrastim in each cycle of
chemotherapy, with a significantly lower incidence of SN for
lipegfilgrastim in cycle 2 (8.5 vs. 21.5%; p-value = 0.013;
Bondarenko et al., 2013). The risk of FN was estimated for
patients with SN transitioning to FN and for those at a risk of
FN subsequent to chemotherapy (base FN risk). The risk of FN
in case of SN was estimated based on the relationship between
granulocytes level and infection (Bodey et al., 1966), and the
FIGURE 1 | Model structure. (A) Model 1: Chemotherapy Markov model. (B)
Model 2: Post-chemotherapy Markov model. The cycle length of the models
were 3 weeks and 1 year for the on-chemotherapy model (model 1) and
post-chemotherapy model (model 2), respectively. SN, severe neutropenia;
FN, febrile neutropenia; RDI, relative dose intensity.
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TABLE 1 | Summary of model parameters.
Parameter Base case value Distribution Source
Transition Probabilities
Baseline risk of FN associated with pegfilgrastim 0.032 Beta (alpha:3.000, beta: 91.000) Bondarenko et al., 2013
OR of FN with lipegfilgrastim vs. pegfilgrastim 0.981 Log-normal (mean of logs:
−0.020, SD of logs: 0.750)
Wang et al., 2015
RR of FN event in chemotherapy cycle ≥ 2 vs. cycle 1 0.213 Log-normal (mean of logs:
−1.562, SD of logs: 0.164)
Whyte et al., 2011; Fust
et al., 2014
Base Risk of FNa
Cycle 1, lipegfilgrastim vs. pegfilgrastim 0.019 vs. 0.019 Based on previous inputs
Cycle 2, lipegfilgrastim vs. pegfilgrastim 0.004 vs. 0.004 Based on previous inputs
Cycle 3, lipegfilgrastim vs. pegfilgrastim 0.004 vs. 0.004 Based on previous inputs
Cycle 4, lipegfilgrastim vs. pegfilgrastim 0.004 vs. 0.004 Based on previous inputs
Risk of additional FN events in subsequent cycles 9.089 Log-normal (mean of logs:
2.188, SD of logs: 0.196)
Whyte et al., 2011; Fust
et al., 2014
Risk of infection in patients with FN 0.300 Beta (alpha: 30.811, beta:
71.893)
Freifeld et al., 2011
Risk of death in patients with FN 0.036 Beta (alpha: 25.461, beta:
3,611.799)
Kuderer et al., 2006; Whyte
et al., 2011
Risk of SN
Cycle 1, lipegfilgrastim vs. pegfilgrastim 0.436 vs. 0.511 Beta (alpha: 41.000 vs. 48.000,
beta: 53.000 vs. 46.000)
Bondarenko et al., 2013
Cycle 2, lipegfilgrastim vs. pegfilgrastim 0.085 vs. 0.215 Beta (alpha: 8.000 vs. 20.000,
beta: 86.000 vs. 73.000)
Bondarenko et al., 2013
Cycle 3, lipegfilgrastim vs. pegfilgrastim 0.086 vs. 0.121 Beta (alpha: 8.000 vs. 11.000,
beta: 85.000 vs. 80.000)
Bondarenko et al., 2013
Cycle 4, lipegfilgrastim vs. pegfilgrastim 0.122 vs. 0.121 Beta (alpha: 11.000 vs. 11.000,
beta: 79.000 vs. 80.000)
Bondarenko et al., 2013
Risk of FN if SN (Based on ANC)b
Cycle 1, lipegfilgrastim vs. pegfilgrastim 0.363 vs. 0.384 Gamma (alpha: 0.900 vs. 0.600,
beta: 1.400 vs. 1.700)
Bodey et al., 1966;
Bondarenko et al., 2013
Cycle 2, lipegfilgrastim vs. pegfilgrastim 0.305 vs. 0.313 Gamma (alpha: 1.500 vs. 1.600,
beta: 1.700 vs. 1.300)
Bodey et al., 1966;
Bondarenko et al., 2013
Cycle 3, lipegfilgrastim vs. pegfilgrastim 0.335 vs. 0.300 Gamma (alpha: 1.300 vs. 1.800,
beta: 1.900 vs. 1.100)
Bodey et al., 1966;
Bondarenko et al., 2013
Cycle 4, lipegfilgrastim vs. pegfilgrastim 0.271 vs. 0.311 Gamma (alpha: 2.500 vs. 1.800,
beta: 1.100 vs. 1.300)
Bodey et al., 1966;
Bondarenko et al., 2013
Risk of Chemotherapy Delay if SNc
Cycle 2, lipegfilgrastim vs pegfilgrastim 0.238 vs. 0.216 Based on the Bayes’ theorem Pettengell et al., 2008;
Bondarenko et al., 2013
Cycle 3, lipegfilgrastim vs. pegfilgrastim 0.256 vs. 0.0307 Based on the Bayes’ theorem Pettengell et al., 2008;
Bondarenko et al., 2013
Cycle 4, lipegfilgrastim vs. pegfilgrastim 0.073 vs. 0.126 Based on the Bayes’ theorem Pettengell et al., 2008;
Bondarenko et al., 2013
Risk of Infection in Patients with SNb
Cycle 1, lipegfilgrastim vs. pegfilgrastim 0.363 vs. 0.384 Gamma (alpha: 0.900 vs. 0.600,
beta: 1.400 vs. 1.700)
Bodey et al., 1966;
Bondarenko et al., 2013
Cycle 2, lipegfilgrastim vs. pegfilgrastim 0.305 vs. 0.313 Gamma (alpha: 1.500 vs. 1.600,
beta: 1.700 vs. 1.300)
Bodey et al., 1966;
Bondarenko et al., 2013
Cycle 3, lipegfilgrastim vs. pegfilgrastim 0.335 vs. 0.300 Gamma (alpha: 1.300 vs. 1.800,
beta: 1.900 vs. 1.100)
Bodey et al., 1966;
Bondarenko et al., 2013
Cycle 4, lipegfilgrastim vs. pegfilgrastim 0.271 vs. 0.311 Gamma (alpha: 2.500 vs. 1.800,
beta: 1.100 vs. 1.300)
Bodey et al., 1966;
Bondarenko et al., 2013
(Continued)
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TABLE 1 | Continued
Parameter Base case value Distribution Source
Risk of Chemotherapy Delay if Infectiond
Cycle 2, lipegfilgrastim vs. pegfilgrastim 0.291 vs. 0.236 Based on the Bayes’ theorem Pettengell et al., 2008;
Bondarenko et al., 2013
Cycle 3, lipegfilgrastim vs. pegfilgrastim 0.314 vs. 0.335 Based on the Bayes’ theorem Pettengell et al., 2008;
Bondarenko et al., 2013
Cycle 4, lipegfilgrastim vs. pegfilgrastim 0.090 vs. 0.138 Based on the Bayes’ theorem Pettengell et al., 2008;
Bondarenko et al., 2013
Risk of death if chemotherapy delay 0.001 Chirivella et al., 2009
Risk of death in patients with SN 0.0005 Beta (alpha: 14.196, beta:
190.064)
Delphi panel
Risk of death if infection 0.036 Beta (alpha: 42.808, beta:
1146.315)
Delphi panel
Risk of hospitalization if FN 0.800 Beta (alpha: 0.364, beta: 0.091) Delphi panel
Proportion of patients with FN managed in outpatient setting 1–risk of hospitalization if FN
Proportion of patients with SN managed in outpatient settinge 1 Assumption
Risk of hospitalization if infection 1 Delphi panel
Risk of RDI < 85% if FN 0.420 Beta (alpha: 9.784, beta: 13.511) (Pettengell et al., 2008)
RR RDI < 85% for age ≥ 65 vs. < 65 years old 1.380 Log-normal (mean of logs:
0.322, SD of logs: 0.027)
Shayne et al., 2006; Lyman,
2009
Risk of RDI < 85%, age < 65 years old, no FN 0.247 Beta (alpha: 18.129, beta:
55.267)
Shayne et al., 2006; Whyte
et al., 2011
OR of RDI < 85%, history of FN vs. no history of FN 1.580 95% CI: 1.200 – 2.100 Shayne et al., 2006
Risk of RDI < 85%, FN naïve, age < 65 years old, lipegfilgrastim vs.
pegfilgrastim
0.044 vs. 0.044 Calculated based on
aforementioned RDI related
values
Risk of RDI < 85%, FN history, age < 65 years old, lipegfilgrastim vs.
pegfilgrastim
0.057 vs. 0.057 Calculated based on
aforementioned RDI related
values
Risk of RDI < 85%, FN naïve, age ≥ 65 years old, lipegfilgrastim vs.
pegfilgrastim
0.060 vs. 0.060 Calculated based on
aforementioned RDI related
values
Risk of RDI < 85%, FN history, age ≥ 65 years old, lipegfilgrastim vs.
pegfilgrastim
0.079 vs. 0.079 Calculated based on
aforementioned RDI related
values
Risk of RDI < 85% if SN 0.280 Beta (alpha: 40.020, beta:
102.909)
(Pettengell et al., 2008)
Risk of RDI < 85%, SN, age < 65 years old, lipegfilgrastim vs.
pegfilgrastim
0.118 vs. 0.118 Calculated based on
aforementioned RDI related
values
Risk of RDI < 85%, SN, age ≥ 65 years old, lipegfilgrastim vs.
pegfilgrastim
0.162 vs. 0.162 Calculated based on
aforementioned RDI related
values
Utility Values
Chemotherapy/G-CSF 0.700 Beta (alpha: 12.633, beta: 5.414) (Ramsey et al., 2009)
SN 0.420 Beta (alpha: 17.769, beta:
24.538)
Gold et al., 2009
Disutility, treatment delay 0.500 Beta (alpha: 1.500, beta: 1.500) Chan et al., 2012
FN inpatient 0.330 Beta (alpha: 35.701, beta:
72.484)
Ramsey et al., 2009
FN outpatientf 0.380 Beta (alpha: 27.176, beta:
44.339)
Assumption
Infection 0.330 Same as FN inpatient Assumption
Breast cancer in years 1–5 0.860 Beta (alpha:3.742, beta: 0.609) Ramsey et al., 2009
Breast cancer in years > 5 0.960 Beta (alpha: 1.399, beta: 0.058) Ramsey et al., 2009
(Continued)
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TABLE 1 | Continued
Parameter Base case value Distribution Source
Costs
Chemotherapy lipegfilgrastim vs. pegfilgrastimg 2,098 vs. 2,098 Gamma (alpha: 44.444 vs.
44.444, beta: 47.211 vs. 47.211)
http://www.bcfi.be/
FN (Inpatient Cost)h
Ward cost 473 Gamma (alpha: 17.472, beta:
27.045)
INAMI/RIZIV, Delphi panel/
Length of stay 6 Gamma (alpha: 7.111, beta:
0.844)
Gladkov et al., 2016
Lipegfilgrastim vs. pegfilgrastimi 2,599 vs. 2,599 Calculate by multiplying the
length of stay by the ward cost.
Conservative assumption
for lipegfilgrastim
Infection if FN, per dayj,k
Cycle 1, lipegfilgrastim vs. pegfilgrastim 3,284 vs. 3,284 Gamma (alpha: 44.444 vs.
44.444, beta: 73.894 vs. 73.894)
BCFI, INAMI/RIZIV, Delphi
panel
Cycle 2, lipegfilgrastim vs. pegfilgrastim 3,282 vs. 3,282 Gamma (alpha: 44.444 vs.
44.444, beta: 73.894 vs. 73.894)
BCFI, INAMI/RIZIV, Delphi
panel
Cycle 3, lipegfilgrastim vs. pegfilgrastim 3,282 vs. 3,282 Gamma (alpha: 44.444 vs.
44.444, beta: 73.894 vs. 73.894)
BCFI, INAMI/RIZIV, Delphi
panel
Cycle 4, lipegfilgrastim vs. pegfilgrastim 3,282 vs. 3,282 Gamma (alpha: 44.444 vs.
44.444, beta: 73.894 vs. 73.894)
BCFI, INAMI/RIZIV, Delphi
panel
Infection if SN, Per Dayk
Cycle 1, lipegfilgrastim vs. pegfilgrastim 3,380 vs. 3,380 Gamma (alpha: 44.444 vs.
44.444, beta: 76.041 vs. 76.041)
BCFI, INAMI/RIZIV, Delphi
panel
Cycle 2, lipegfilgrastim vs. pegfilgrastim 3,372 vs. 3,372 Gamma (alpha: 44.444 vs.
44.444, beta: 76.041 vs. 76.041)
BCFI, INAMI/RIZIV, Delphi
panel
Cycle 3, lipegfilgrastim vs. pegfilgrastim 3,372 vs. 3,372 Gamma (alpha: 44.444 vs.
44.444, beta: 76.041 vs. 76.041)
BCFI, INAMI/RIZIV, Delphi
panel
Cycle 4, lipegfilgrastim vs. pegfilgrastim 3,372 vs. 3,372 Gamma (alpha: 44.444 vs.
44.444, beta: 76.041 vs. 76.041)
BCFI, INAMI/RIZIV, Delphi
panel
Outpatient setting, FN 44 Beta (alpha 16,056; beta 2.724) BCFI, INAMI/RIZIV, Delphi
panel
aEstimates dependent on the risk estimate used (i.e., RR of 0.981 as per Wang et al., 2015 or OR of 0.340 as per Bond et al., 2015). Calculation are herein based on Wang et al.
bA gamma distribution was assigned to the ANC based on the mean ANC published by Bondarenko et al. for lipegfilgrastim and pegfilgrastim and 1,000 iterations were generated.
Then, ANC < 0.5 × 109/L were used to derived the risk of FN/infection, thanks to the correlation established by Bodey et al. between granulocyte levels and risk of infection. It was
then conservatively assumed that the risk of FN is the same as the risk of infection in patients with SN. Patients with SN without fever, signs, or symptoms ofinfection do not receive
treatment in the hospital, but are followed up for potential development of fever at home.
cThe risk of delay was calculated based on the Bayes’ theorem (conditional probability): P(SN|delay)
P(Non−SN|delay) =
P(delay|SN)
P(delay|Non−SN) *
P(SN)
P(Non−SN) ; P
(
Non− SN| delay
)
= 1 − P(SN|delay) and
P(Non− SN) = 1− P(SN). The probability of delay in patients with SN and the probability of delay in patients without SN were as follow: P
(
delay| SN
)
= 0.42 and P
(
delay| Non− SN
)
= 0.32 (Pettengell et al., 2008). The probability of SN across all cycles was 0.500 and 0.585 for lipegfilgrastim and pegfilgrastim, respectively (Bondarenko et al., 2013).
dThe same approach as the risk of delay in patients with FN was considered. However, it was assumed that the risk of delay in patients with infection is the same as the risk of delay
in patients with FN. The probability of delay in patients with FN and the probability of delay in patients without FN were as follow: P (delay|FN) = 0.42 and P (delay|Non− FN) = 0.32
(Pettengell et al., 2008). The probability of FN across all cycles was 0.635 and 0.649 for lipegfilgrastim and pegfilgrastim, respectively. These probabilities were calculated from the
baseline risk of FN (therefore dependent on risk estimate used as per Wang et al. or Bond et al. – here Wang et al.), the risk of additional FN in subsequent cycles and the estimated risk
of FN in patients with SN.
ePatients with SN without fever, signs, or symptoms ofinfection do not receive treatment in the hospital, but are followed up for potential development of fever at home. No cost was
imputed for the management of SN in the outpatient setting.
fThe difference (i.e., 0.05) between utilities for patients hospitalized for FN vs. those treated in an outpatient setting as per Lathia et al. (2013) was simply applied.
gTreatment costs were composed of the unit cost of G-CSF (lipegfilgrastim or pegfilgrastim) : e1,169; cost of chemotherapy agents docetaxel (20 mg/ml): e68; and doxorubicine TEVA
(10 mg/5 ml): e8 (CBIP-BCFI BCfPI, 2015); and G-CSF administration cost: e8 (Annemans et al., 2001). G-CSF administration costs were inflated to 2015 using the Harmonized Index
of Consumer Price for Health (Federal Reserve Bank of St.Louis, 2015). Chemotherapy agent related costs were adjusted to a female patient with a BMI of 26 kg/m2 and a weight of
73.9 kg.
hOf note, in the model, the costs of empirical antibiotic treatment was also considered. If a patient is admitted at the hospital with FN, “empiric” antibiotic therapy is initiated at admission.
Piperacilline-tazobactam 4 × 4 g/d is commonly used and treatment is stopped when until restitution of neutrophils > 1,000/mm3 AND free of fever after 48 h AND negative bacterial
cultures. Median time of treatment duration with piperacilline-tazobactam for breast cancer patients is 4 days. The ward cost was calculated as the average of the daily cost for all
Belgian hospitals.
iThe time in hospital, day, mean (SD) was 1 (0) and 5.5 (0.7) for lipegfilgrastim and pegfilgrastim based on the Bondarenko head-to-head trial, respectively (Gladkov et al., 2016). This
would have resulted in FN hospital costs of 473 vs. 2,599 for lipegfilgrastim vs. pegfilgrastim. Because the only patient who was hospitalized for FN was excluded for protocol violation
(Bondarenko et al., 2013), we conservatively assumed that the length of stay for lipegfilgrastim would be the same as of pegfilgrastim. The value of 5.5 days was rounded up to 6 days.
jThe duration of antibiotic use was considered to be 5 days for both treatment arms given that no significant difference in antibiotic use have been demonstrated between the two
G-CSFs (Bondarenko et al., 2013; Mhaskar et al., 2014; Gladkov et al., 2016).
kWeighted average calculated based on the following prevalence of infection: bacteremia: 60.0%, sepsis: 22.5%, pneumonia: 8.1% and fungal infection: 9.4% (assumption).
BCFI, Belgian Centre for Pharmacotherapeutic Information; FN, febrile neutropenia; OR, odds ratio; RR, relative risk; SN, severe neutropenia. The transition probabilities were validated
in a modified Delphi panel and are reflective of current clinical practice and management of chemotherapy-induced neutropenia and related complications in patients with breast cancer
in Belgium.
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probability of ANC less than 0.5 × 1010/L (Bondarenko et al.,
2013). It was then conservatively assumed that the risk of FN is
the same as the risk of infection.
The base risk of FN for lipegfilgrastim was calculated
from the risk of FN in the pegfilgrastim group to which
was applied a risk estimate for FN for lipegfilgrastim vs.
pegfilgrastim. This adjustment was considered appropriate given
that in the Bondarenko study, the only patient who had FN
in the lipegfilgrastim arm was excluded for protocol violation
(Bondarenko et al., 2013). As mentioned earlier, two meta-
analyses reported two different risk estimates for FN for
lipegfilgrastim vs. pegfilgrastim. Wang et al. reported an OR of
0.98 (95% CI: 0.21–4.53) based on a direct comparison between
lipegfilgrastim and pegfilgrastim in breast cancer patients. The
indirect comparison included trials vs. placebo or no-G-CSF in
different patient populations (breast cancer, colorectal cancer,
non-Hodgkin lymphoma, lung and ovarian cancer), resulting in
an OR of 2.00 (95% CI: 0.47–8.11). The result of the combination
of direct and indirect comparisons was between the results of
the direct and the indirect comparison, with an OR of 1.39
(0.54–3.50) (Wang et al., 2015). Bond et al., on the other hand,
reported a RR of 0.34 (95% CI: 0.05–2.14) in a direct comparison
between lipegfilgrastim vs. pegfilgrastim (Bond et al., 2015).
Given (i) the recommendations of the Cochrane Handbook
for Systematic Reviews of Interventions stating that direct
comparison should take precedence over indirect comparison
in forming conclusions (The Cochrane Collaboration, 2011), (ii)
the application of inconsistent indirect or mixed methods by
Wang et al. that led to potentially biased risk estimates not in
the alignment with the head to head trial results (Lehmacher
et al., 2016), risk estimates from direct comparison in breast
cancer patients were considered relevant in the current study.
The base analyses were performed using an OR of 0.98 (95%
CI: 0.21–4.53) and a RR of 0.34 (95% CI: 0.05–2.14). All other
transition probabilities were derived from literature or adjusted
for lipegfilgrastim and pegfilgrastim wherever needed.
Post-Chemotherapy Model (Model 2)
RDI is the ratio of the actual dose of chemotherapy delivered to
the intended dose of the standard chemotherapy regimen over
a specific time. Decreases in RDI can be results of dose delays
and dose reductions. Although controversial, the relationship
between RDI and patient outcomes is well described in the
literature (Bonadonna et al., 2005; Pettengell et al., 2008; Bretzel
et al., 2009; Chirivella et al., 2009; Aapro et al., 2011); and several
studies address the significance of achieving an RDI of more
than 85% (Bonadonna et al., 2005; Lyman, 2008). Age, SN and
FN are predictors of receiving RDI less than 85% (Shayne et al.,
2006; Pettengell et al., 2008; Whyte et al., 2011). Gladkov et al.
reported that at least 98% of patients in the lipegfilgrastim and the
pegfilgrastim received the planned chemotherapy dose (Gladkov
et al., 2016). Consequently, the risk of RDI less than 85% was
assumed to be the same for both G-CSFs (Pettengell et al., 2008).
It was further adjusted for age, incidence of SN, incidence of
FN and FN history (Leonard et al., 2003; Shayne et al., 2006;
Chirivella et al., 2009; Lyman et al., 2009; Whyte et al., 2011).
The impact of RDI on survival was considered next. The
estimation of the risk of death if RDI less than 85% was as
per Whyte et al.’s formula that is based on the risk of RDI less
than 85% when experiencing neutropenic events and the survival
hazard ratio (Whyte et al., 2011). The literature suggests that for
anthracycline-based regimens, 32% of patients who experienced
neutropenic events receive RDI less than 85%, compared with
7% for those who do not experience these events (Leonard
et al., 2003). Additionally, a hazard ratio of 1.32 was seen for
survival associated with an RDI ≥ 85% vs. an RDI < 85%
(Lyman et al., 2009). The model applies this hazard ratio to
the survival of patients with low RDI in the first 5 years of the
post-chemotherapy model. After and for the remainder of their
lifetime, all-cause mortality as per the general population applied
as it was assumed that breast cancer survivors were cured after
5 years. Breast cancer specific mortality data by stage and age
were obtained from the Belgian Cancer Registry and all-cause
mortality data from Belgian life tables (data on file).
Utility Values
Health utilities, which vary between 0 (death) and 1 (ideal health)
were used to calculate the QALYs. Utility values were obtained
from the literature for breast cancer during chemotherapy, SN,
FN/infection, breast cancer survivor during years one to five
and breast cancer survivor after year five (Table 1). A disutility
factor was assigned to treatment delay. QALYs were calculated by
multiplying life years gained over the course of the chemotherapy
and post-chemotherapy models by utility values.
Resource Use and cost Data
Delphi Panel Survey
Resource use data were obtained from a random selection of
64 oncologists and hematologists through a modified Delphi
survey methodology. The Delphi survey was conducted in two
consecutive rounds. Based on identified treatment pathways,
a questionnaire was developed with closed-ended questions
about medication, laboratory tests, and diagnostic procedures
and open-ended questions about additional information (e.g.,
to obtain empirical data as opposed to protocol-driven clinical
research data). In the first round, the survey was conducted via a
web-based application, SurveyMonkey R© , yielding 11 responses
out of 64 experts recruited. The results were analyzed as median,
25th, and 75th percentile outcomes. In the second round, results
obtained were presented to the 11 participating respondents via
email or by means of a face-to-face interview to validate/adjust
the results, yielding 7 responses with narrower variances between
outcomes.
Costs Associated with Severe Neutropenia, Febrile
Neutropenia, Infection and Delay
Resource use related to: G-CSFs (lipegfilgrastim and
pegfilgrastim), medication (antibiotics and antifungals),
chemotherapy regimen, laboratory tests, diagnostic procedures
(e.g., X-ray, CT-scan), type and duration of hospitalization (e.g.,
emergency room, oncology ward) were taken into account.
Medical procedures related costs were obtained from the
Nomensoft database on the INAMI/RIZIV website (National
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Institute for Health and Disability Insurance (RIZIV-INAMI),
2015a). Drug cost data (in 2015 euros – e), which were derived
from the Belgian Center of Pharmacotherapeutic Information
website (CBIP-BCFI BCfPI, 2015), were collected for the drugs
currently prescribed for the treatment of SN, FN and associated
complications. The modified Delphi survey yielded data about
the use of antibiotics and antifungals for the four most common
infections following SN and FN, being bacteremia, sepsis,
pneumonia, and fungal infections (Kuderer et al., 2006). An
average antibiotics treatment duration of 5 days for hospitalized
patients with FN was considered in both treatment arms
(Mhaskar et al., 2014). Treatment costs for antibiotics and
anti-fungal medication were computed as a weighted average of
the cost per treatment course, taking relative market share into
consideration.
The per diem cost of hospitalization was computed from data
obtained from the NIHDI website (National Institute for Health
and Disability Insurance (RIZIV-INAMI), 2015b) taking the
mean of all listed acute care facility admission costs in Belgium.
Daily costs for hospital stay, laboratory and microbiological tests
as well as radiology procedures were calculated and adjusted to
length of stay.
With respect to FN, inpatient and outpatient costs were
considered. The hospitalization length of stay was derived from
Gladkov et al. (2016), whilst it was assumed that the risk of
hospitalization was similar between the two G-CSFs and did
not differ between cycles. With the FN outpatient costs, it was
assumed that patients were treated for seven to 10 days with per
oral amoxicillin/clavulanic acid 2 × 2 g/day as per the clinical
practice (data on file).
Finally, there were no costs imputed for the management of
SN (only in the outpatient setting) and of chemotherapy delay.
There were also no costs associated with the post-chemotherapy
model.
Base Case Analysis
Model parameters base values were defined and differences
on costs and QALYs between the lipegfilgrastim group
and the pegfilgrastim group calculated. The incremental
cost-effectiveness ratio (ICER), calculated as the ratio of
the incremental costs to the incremental QALYs between
lipegfilgrastim and pegfilgrastim, was calculated when
appropriate. Analyses were performed over a lifetime horizon.
Costs and QALYs were discounted at a rate of 3 and 1.5%,
respectively following guidelines of the Belgian Health Care
Knowledge Centre (KCE) (Cleemput et al., 2012). Effectiveness
was also reported in terms of life-years gained (LYG) that were
not discounted since they were expected to be valuable in the
future as at present. In comparison to LYG, QALYs involve both
quantitative and qualitative components that are likely to be
less valuable in the future as at present, and are also likely to be
subject to higher uncertainty (Peura et al., 2008).
One-Way Sensitivity Analysis
One-way sensitivity analysis (OWSA) and probabilistic
sensitivity analyses (PSA) were conducted to test both parameter
and model uncertainty. In the OWSA, sensitivity ranges of
parameters included either 95% CIs, where data was available, or
the estimated variability of ±30% of the mean value. Tornado
diagrams were used to present the results of the OWSA and to
depict the parameters that mostly affect both costs and QALYs.
With the PSA, the impact of joint uncertainty among all input
parameters on cost-effectiveness outcomes was captured by
assigning a probability distribution to each parameter and
using 5,000 random samples from parameter distributions. A
cost-effectiveness acceptability curve (CEAC) was subsequently
drawn, showing the probability of lipegfilgrastim being cost-
effective for various levels of willingness to pay (WTP) per QALY
gained.
Price Threshold Analysis
A price threshold analysis was subsequently conducted to
determine the upper limit of the price of lipegfilgrastim to
be considered cost-effective, using a WTP of e30,000 per
QALY gained (corresponding approximately to the Belgian Gross
Domestic Product). The analysis was carried out across breast
cancer stages and age bands of 35–45, 45–55, 55–65, 65–75, and
over 75 years. The analysis was based on the netmonetary benefit,
which is the difference between monetized benefits and costs
between lipegfilgrastim and pegfilgrastim. Interventions with a
positive net monetary benefit are deemed cost-effective as the
associated cost is less than the value of the additional benefit
achieved.
RESULTS
Base Case Analysis
The average costs and QALYs of primary prophylaxis with
lipegfilgrastim compared to pegfilgrastim for patients with stages
II-IV breast cancer are presented in Table 2 Cost-effectiveness
results. Results are presented for an OR of 0.98 and a RR
of 0.34 for the risk of FN for lipegfilgastim compared to
pegfilgrastim. With an OR of 0.98, the average costs per patient
and QALYs for lipegfilgrastim weree9,845 and 13.977 compared
to e10,208 and 13.925 for pegfilgrastim. Life expectancy in the
lipegfilgrastim group was further increased by 0.058 years on
average (i.e., 21 life-days gained) compared with pegfilgrastim.
Similarly, when using a RR of 0.34, lipegfilgrastim was the
dominant strategy with lower costs and higher QALYs compared
to pegfilgrastim. In the analysis of LYG, an average increase
by 0.059 years (i.e., 22 life-days gained) was estimated in
the lipegfilgrastim group compared to the pegfilgrastim group.
Overall, these results indicated that lipegfilgrastim was a
dominant strategy in the base case. Consequently, the ICER
was not calculated. Given the consistency in conclusions when
using either an OR of 0.98 or a RR of 0.34 for the risk
of FN for lipegfilgrastim compared to pegfilgrastim, following
results will be limited to the analyses conducted with an OR of
0.98.
In deterministic analyses, 41% of the cost-savings came
from avoided infection cases and associated costs when
comparing lipegfilgrastim with pegfilgrastim. Twenty eight
percent of the cost-savings were associated with avoided SN
cases, 21% with avoided FN cases and 10% with avoided
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TABLE 2 | Cost-effectiveness results for lipegfilgrastim compared to pegfilgrastim.
Results based on Wang et al.’s risk estimate for FN,
lipeg vs. peg: OR = 0.98)
Results based on Bond et al.’s risk estimate for FN,
lipeg vs. peg: RR = 0.34)
Costs (e) QALYs LY Costs (e) QALYs LY
Lipegfilgrastim 9,845 13.977 21.204 9,796 13.997 21.210
Pegfilgrastim 10,208 13.925 21.145 10,205 13.944 21.151
Difference −363 0.052 0.058 −410 0.054 0.059
Analyses were performed with an odd ratio of 0.98 (direct comparison in patients with breast cancer as per Wang et al., 2015) and with a relative risk of 0.34 (direct comparison in
patients with breast cancer as per Bond et al., 2015). Mean costs, QALYs and LY were the average of 5,000 simulated estimates. Numbers are rounded so some differences may
appear to be off. LY, life years; OR, odds ratio; QALYs, quality-adjusted life years gained; RR, relative risk.
chemotherapy delay. Conclusively, there were fewer patients who
experienced CIN-related complications and associated costs in
the lipegfilgrastim group compared to the pegfilgrastim group.
The chemotherapy/G-CSF costs were offset by higher costs
associated with CIN-related complications; and particularly with
infection. The difference in QALYs was attributable to the
difference in the number of patients in the chemotherapy/ G-CSF
Markov state followed by infection, FN, SN and chemotherapy
delay.
One-Way Sensitivity Analysis
The impact of each of the model parameter on incremental costs
and QALYs was explored in OWSA (Figure 2). For all scenarios
within the possible ranges of model inputs, lipegfilgrastim
remained less costly compared to pegfilgrastim; except when
increasing the cost of lipegfilgrastim by 30%. The cost of
lipegfilgrastim had the largest impact on the incremental costs,
followed by the risk of FN in patients with SN in cycle 1
for lipegfilgrastim and the risk of SN following chemotherapy
in cycle 1 for lipegfilgrastim. Incremental QALYs were most
sensitive to variance in age, in the proportion of patients with
stage III and II breast cancer and in the utility value for cancer
survivors after year five. Overall, QALYs gained decreased as
age increased; and increased as the proportion of patients with
stage III and II breast cancer increased. Additionally, QALYs
gained increased as the utility for cancer survivors after year five
increased.
The effect of joint parameter uncertainty on outcomes is
illustrated in the cost-effectiveness plane. Figure 3 shows that
lipegfilgrastim was associated with greater QALYs in 87% of
the 5,000 simulations (northeast and southeast quadrants), and
in over half of the simulations, lipegfilgrastim was dominant
(southeast quadrant). Figure 4 indicates that the likelihood that
lipegfilgrastim is cost-effective vs. pegfilgrastim increases as
the WTP increases (i.e. gains in QALYs become increasingly
rewarded), reaching 68, 79, and 83% at the WTP thresholds of
e10,000, e30,000, and e50,000 per QALY gained, respectively.
The probability that lipegfilgrastim is cost-saving is indicated by
the probability at a WTP of zero (where no value is placed on the
health benefits), which was 57%.
Price Threshold Analysis
Figure 5 shows that at currently equivalent price with
pegfilgrastim, lipegfilgrastim is dominant across all cancer
stages and age bands. Lipegfilgrastim remained cost-effective
across all cancer stages and age bands up to a price point of
e1,500 at a WTP of e30,000 per QALY gained. Between e1,500
and e2,000, lipegfilgrastim is cost-effective in some age groups
and is no longer cost-effective in all cancer stages and age bands
at a price higher than e2,000.
DISCUSSION
Long-acting G-CSFs, lipegfilgrastim, and pegfilgrastim, are
administered once per chemotherapy cycle to reduce the
duration of SN and the incidence of FN. This study evaluated the
cost-utility of lipegfilgrastim compared to pegfilgrastim, with a
particular focus on the following outcomemeasures: incidence of
SN, incidence of FN, infection, chemotherapy dose delay and RDI
less than 85%. In addition, QALYs and LYs gained were captured
as standard measures of effect.
This analysis has demonstrated that lipegfilgrastim is a more
cost-effective strategy compared to pegfilgrastim over the lifetime
of patients with stage II-IV breast cancer. The cost-savings came
merely from the decrease in infection and SN cases. OWSA
further indicated that cost-savings were sensitive to the risk of FN
in patients with SN and the risk of SN following chemotherapy
in cycle 1. Overall, these results align with the literature, which
shows that SN places patients at high risk of infection and
the risk of FN increases in direct proportion to the severity
and duration of neutropenia and occurs most frequently early
in a course of chemotherapy (Lyman et al., 2003; Lyman and
Rolston, 2010; Freifeld et al., 2011; Saloustros et al., 2011). In
our study, the risk of FN/infection in patients with SN was
based on the relationship between granulocyte levels and the
risk of infection as established by Bodey et al. in patients with
acute leukemia (Bodey et al., 1966). Therefore, further studies
on the relationship between granulocyte or ANC levels and the
risk of FN/ infection in patients with breast cancer may be
important. This could further be relevant when considering that
lipegfilgrastim is associated with higher neutrophil count at the
end of a chemotherapy cycle than pegfilgrastim (Bondarenko
et al., 2013); suggesting that fewer patients might be at a risk of
developing FN or to experience SN in subsequent chemotherapy
cycles. Indeed, this was observed in the second chemotherapy
cycle in Bondarenko et al.’s study. Finally, it should be mentioned
that cost-savings were influenced the most by the variation
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FIGURE 2 | One-way sensitivity analysis for incremental cost and QALY. Tornado diagram displaying the results of the one-way sensitivity analysis. The diagram
shows the correlation between ±30% variation in model parameters and the distribution of costs and QALYs. Only the top 10 influential parameters of the incremental
costs and QALYs are displayed. BC, breast cancer; chemo, chemotherapy; FN, febrile neutropenia; G-CSF, granulocyte colony-stimulating factor; lipeg,
lipegfilgrastim; QALYs, quality-adjusted life years; SN, severe neutropenia.
FIGURE 3 | Cost-effectiveness plane for lipegfilgrastim compared to pegfilgrastim. Plot of the results of the probabilistic sensitivity analysis for 5,000 simulations. The
x-axis represents the difference in QALYs and the Y-axis the difference in costs between lipegfilgrastim and pegfilgrastim. Seven percent of the estimates lie in the
north-west quadrant (pegfilgrastim dominates), 36% in the north-east quadrant (lipegfilgrastim is more effective but more expensive), 7% in the south-west quadrant
(lipegfilgrastim is cheaper but less effective) and 51% in the south-east quadrant (lipegfilgrastim dominates pegfilgrastim). Simulations spanned all four quadrants of
the cost-effectiveness plane, indicating some level of uncertainty around the base case estimate (cost-savings of e363 and QALYs gained of 0.052). 1QALYs,
incremental quality-adjusted life years; 1Costs, incremental costs.
in the cost of lipegfilgrastim. In Belgium, lipegfilgrastim and
pegfilgrastim have the same price. The price threshold analysis
suggested that lipegfilgrastim is cost-effective up toe1,500 across
all age bands and cancer stages, compared to the current price of
e1,169.
Effectiveness results were largely influenced by the patient age,
breast cancer stage at diagnosis and the utility value for cancer
survivors after year five. This was in line with previous cost-
effectiveness studies reporting on these parameters as drivers of
the cost-effectiveness of G-CSFs for the prevention of FN after
chemotherapy (Lyman, 2009; Ramsey et al., 2009; Whyte et al.,
2011). The impact of age on the cost-effectiveness results was
expected given the age-dependent risk of RDI less than 85%
(Shayne et al., 2006) and the relative impact on overall mortality.
Further research on utility weights associated with breast cancer
survivors after year five is required given the sensitivity of
different cost-effectiveness studies on this parameter.
In a European survey relating to cancer therapy and
neutropenic infections, Leonard reported that oncology nurses
recognize that minimizing the risk of infection and FN as
being important for achieving a successful outcomes in cancer
therapy (Leonard, 2012). From a patient perspective, the majority
reported having their chemotherapy delayed or changed as a
result of neutropenia, infection or FN. Therefore, despite being
broaden to major CIN-related complications, the value of our
model derives merely from the most serious chemotherapy
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FIGURE 4 | Cost-effectiveness acceptability curve.
FIGURE 5 | Price threshold analysis. Lipegfilgrastim price was varied across breast cancer stages and age bands of 35–45, 45–55, 55–65, and over 75 years old to
examine efficient reimbursement prices. The analysis was conducted at a willingness to pay threshold of e30,000 per QALY gained. Each dot represents an
incremental net monetary benefit value for a specific age at a given price point. Of note, the analysis was conducted keeping the following distribution of breast cancer
stage constant: stage II: 38.6%, stage III: 47.5% and stage IV: 13.9%. Positive incremental net monetary benefit values indicate that lipegfilgrastim is cost-effective
compared to pegfilgrastim. On the other hand, negative incremental net monetary benefit values indicate that lipegfilgrastim is not cost-effective compared to
pegfilgrastim. Up to a price point of e1,500, all incremental net monetary benefit value are greater than zero. At higher price point, lipegfilgrastim shows to no longer
be cost-effective for some age groups.
complications (i.e., SN, FN, and infection) health professionals
deal with in their practice, those for which treatment algorithms
and guidelines have been developed and that impact the most the
patients (Aapro et al., 2006, 2011; Freifeld et al., 2011).
The results of our study aligned with Kulikov et al. (2016)
but disagree with those obtained by Fust et al. (2015, 2016),
who found pegfilgrastim to be dominant when compared to
lipegfilgrastim. This difference in conclusion may arise from
the study design. From a clinical standpoint, Fust et al.’s model
was populated with an OR of 1.39 for the risk of FN in
lipegfilgrastim vs. pegfilgrastim. As mentioned earlier, Wang
et al. reported an OR of 1.39 as a result of an MTC and
an OR of 0.98 as a result of the direct comparison between
lipegfilgrastim and pegfilgrastim in patients with breast cancer
only, both risk estimates being non-statistically significant (Wang
et al., 2015). By not relying on the head-to-head trial comparing
lipegfilgrastim and pegfilgrastim and by using an OR of 1.39
that stem from an indirect and MTC analyses that lack validity
(Lehmacher et al., 2016), the incremental savings and utilities
reported by Fust et al. may have been overestimated. Our
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analysis aligns with the requirements of leading institutions for
health technology assessment (HTA) such as the Belgian KCE
(Cleemput et al., 2012), the Canadian Agency for Drugs and
Technology in Health (CADTH) (CADTH, 2006), the National
Institute for Health and Clinical Excellence NICE, 2013) and
the German Institute for Quality and Efficiency in Health Care
(IQWIG) (IQWIG, 2012) that have a preference for data from
head-to-head randomized controlled trials. Indirect treatment
comparison methods may be used if data from head-to-head
trials are not available.
Inconsistencies were further noted in Fust et al.’s model
when considering costs. Consistent with the clinical effects
and the potential for leucocytosis, white blood cell counts
should be performed at regular intervals during therapy for
both pegfilgrastim and lipegfilgrastim (Lonquex, 2015; Neulasta,
2015). However, this was applied only to lipegfilgrastim in
Fust et al.’s model, at the rate of five complete blood
counts vs. only one complete blood count prior chemotherapy
with pegfilgrastim, potentially overestimating lipegfilgrastim
treatment costs. Finally, outpatient FN costs in Fust et al. were as
per the USA setting whilst our analysis reflects the Belgian clinical
practice.
It could also be argued that the current model differs from
Fust et al. in its structure and the selected population. Indeed,
the current study focuses on stage II-IV breast cancer patients,
whereas Fust et al. reported data on stage II breast cancer patients.
There are several limitations to the current study, the most
important one being that currently, there is no direct clinical
evidence that CIN leads to clinically recognized chemotherapy
delay, lower RDI or poorer survival. However, it could be
considered that this was well mitigated in the model as clinical
data were used wherever possible. As such, similarity in the use
of antibiotics or the fact that almost all patients had received the
planned chemotherapy dose in both treatment arms were well
reflected in the model. Next, resource use data were obtained in
fine from only seven oncologist, holding the potential of a non-
representative assessment of resource use. Post-chemotherapy
costs were assumed to be zero given that the cost of G-
CSFs and associated costs were captured in the chemotherapy
model (model 1). In addition, there is limited data concerning
the impact of RDI on resource utilization and associated
costs. Furthermore, the treatment costs for bacteraemia, sepsis,
pneumonia, and fungal infection were considered independently.
However, such infections are not mutually exclusive. Other
types of infection (urinary tract infections, skin and deep tissue
infections, mucosal infections, upper respiratory tract infections,
etc.) may occur. Sensitivity analyses indicated that costs for
treating infections as a result of SN or FN events and the
relative incidence of type of infection were not drivers of the
incremental costs. Importantly, translating the granulocyte levels
into a risk of infection was based on patients with leukemia
(Bodey et al., 1966) given the lack of data in patients with breast
cancer.
Our analysis considered the payer’s perspective, whereas a
societal perspective may be important in other circumstances
(Weinstein et al., 1996). Including indirect costs, such as patient
time, caregiver costs and lost productivity may improve the cost-
effectiveness of lipegfilgrastim compared to pegfilgrastim. Finally,
although patients with chemotherapy dose delay have about one
percent risk of relapse (data on file), relapse was not captured in
the present model.
In conclusion, this analysis shows that, for equivalent drug
costs, lipegfilgrastim is a dominant strategy compared to
pegfilgrastim for the management of patients with stage II-IV
breast cancer. Lipegfilgrastim shows to be cost-effective up to
e1,500 across all age bands and cancer stages, compared to the
current price of e1,169.
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